Retatrutide

Discreet packaging • UK dispatch • Tracked delivery • Stored cold (2–8°C) prior to shipping

Retatrutide is a triple-agonist peptide widely researched for metabolic signalling pathways.
It targets GLP-1, GIP, and glucagon receptors.

Retatrutide is an investigational, once-weekly injectable “triple G” agonist developed by Eli Lilly for obesity and type 2 diabetes. By targeting GLP-1, GIP, and glucagon receptors, it significantly reduces appetite and increases fat metabolism, with Phase 2 trials showing up to 24.2% weight loss at 48 weeks. Currently in Phase 3 trials.

Ready to order? Select your quantity above and add to bag.

Strictly for in vitro or qualified laboratory/animal research use only—not for human consumption or diagnostic/therapeutic application. Store refrigerated (2–8°C) for stability. Shipped discreetly from the UK worldwide to research facilities.